Welcome to our dedicated page for Mesoblast SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mesoblast Limited SEC filings document its foreign-issuer reporting through Form 6-K submissions that incorporate Australian Securities Exchange announcements, Appendix 4C activity reports, press releases, and R&D presentation materials. The disclosures cover Ryoncil® commercialization, operating cash activity, and clinical programs built around allogeneic mesenchymal lineage stromal cell products.
The filing record also includes ASX notices for director interests, cessation of securities, unquoted equity securities, and applications for quotation of securities. These materials describe capital-structure changes, governance reporting, product and platform updates, and the company’s Form 20-F foreign private issuer framework.
Mesoblast Limited submitted a foreign issuer report describing an action first disclosed on the Australian Securities Exchange. On December 17, 2025, the company lodged an Appendix 3G with the ASX, which relates to a new issue announcement and the issue, conversion or payment up of unquoted equity securities. This Appendix 3G document is attached to the report as an exhibit and is incorporated by reference for further details.
Mesoblast Limited submitted a foreign issuer report describing an action first disclosed on the Australian Securities Exchange. On December 17, 2025, the company lodged an Appendix 3G with the ASX, which relates to a new issue announcement and the issue, conversion or payment up of unquoted equity securities. This Appendix 3G document is attached to the report as an exhibit and is incorporated by reference for further details.
Mesoblast Limited submitted a Form 6-K to provide U.S. investors with materials it filed with the Australian Securities Exchange. The report states that on November 25, 2025, the company lodged the Chair’s Annual General Meeting address and the CEO’s presentation to the Annual General Meeting, which are included as Exhibits 99.1 and 99.2. It also includes a press release dated the same day as Exhibit 99.3. These documents are incorporated by reference, making the Australian-market communications available to investors following Mesoblast’s U.S. listing.
Mesoblast Limited, an Australia-incorporated company, submitted a Form 6-K as a foreign private issuer. The report forwards a news release announcement that Mesoblast filed with the Australian Securities Exchange on November 5, 2025, attaching it as Exhibit 99.1 and incorporating it by reference.
The filing is signed on behalf of Mesoblast Limited by Company Secretary Paul Hughes, dated November 5, 2025.
Mesoblast Limited furnished a Form 6-K to provide investors with Australian Securities Exchange materials. The filing attaches two ASX documents dated October 28, 2025: an Appendix 3Y change of director’s interest notice and an Appendix 3G notification of issue, conversion or payment up of unquoted equity securities, incorporated by reference as Exhibits 99.1 and 99.2.
This update is administrative, making the ASX disclosures available to U.S. investors under the Exchange Act.
Mesoblast Limited furnished a Form 6-K to provide investors with Australian Securities Exchange materials. The filing attaches two ASX documents dated October 28, 2025: an Appendix 3Y change of director’s interest notice and an Appendix 3G notification of issue, conversion or payment up of unquoted equity securities, incorporated by reference as Exhibits 99.1 and 99.2.
This update is administrative, making the ASX disclosures available to U.S. investors under the Exchange Act.
Mesoblast Limited furnished a Form 6-K detailing the availability of key shareholder materials filed with the Australian Securities Exchange. The submission includes the company’s Annual Report to Shareholders, a Notice of Annual General Meeting, and an Appendix 4G with Corporate Governance Statement, each attached as Exhibits 99.1, 99.2, and 99.3 and incorporated by reference.
Mesoblast reports as a foreign private issuer and files annual reports under Form 20-F. The filing identifies Australia as the jurisdiction of incorporation and lists the principal office at Level 38, 55 Collins Street, Melbourne 3000, Australia. The report was signed by Company Secretary Niva Sivakumar on October 28, 2025.